One in the eye for Roche as French pursue off-label Avastin
This article was originally published in SRA
Executive Summary
The French regulatory agency ANSM has begun the process of allowing Roche's VEGF inhibitor, Avastin (bevacizumab), to be used off-label in wet age-related macular degeneration (AMD), taking advantage of new legislation passed earlier this year.